diet Fermented Foods / neuroP Cancer Research Results

dietF, diet Fermented Foods: Click to Expand ⟱
Features:
Fermented Food. Some studies suggest that certain fermented foods (such as yogurt, kefir, sauerkraut, kimchi, and miso) can have health-promoting properties. These benefits may be due to probiotics (beneficial bacteria), bioactive compounds, and fermentation-derived metabolites.

• Probiotics have been investigated for their potential to improve gut health and modulate the immune system. A robust gut microbiome may play a role in reducing systemic inflammation, which has been linked to a lower risk of several chronic diseases, including some types of cancer.

• Fermented foods are often just one component of a diverse diet rich in fruits, vegetables, whole grains, and lean proteins, which collectively can contribute to a reduced risk of chronic diseases.

https://haelan951.com/
https://avemar.com/

Dietary fermented foods — foods and beverages produced through controlled microbial growth and enzymatic conversion of food constituents. This dietary category includes yogurt, kefir, cultured vegetables, kimchi, sauerkraut, miso, tempeh, natto and selected fermented beverages. It is formally classified as a microbiome-modulating dietary intervention rather than a drug, defined probiotic or standardized therapeutic product. The database abbreviation is dietF. Effects depend strongly on the food substrate, microbial strains, fermentation conditions, processing, storage and serving size. Fermented foods may deliver viable microorganisms, microbial structural components and fermentation-derived metabolites, but not every fermented food contains live organisms or clinically validated probiotic strains.

Primary mechanisms (ranked):

  1. Modulation of gut microbial community structure and function by food-associated microorganisms, microbial substrates and fermentation-derived metabolites.
  2. Enhancement of intestinal epithelial-barrier integrity and competitive suppression of potentially pathogenic or pro-inflammatory microorganisms.
  3. Immune modulation, including reduced systemic inflammatory signalling and altered innate and adaptive immune-cell activation.
  4. Generation or delivery of bioactive metabolites, including organic acids, short-chain fatty-acid-related substrates, peptides, transformed polyphenols and microbial cell-wall components.
  5. Modification of dietary carcinogen exposure through altered microbial metabolism, improved food preservation and degradation of selected antinutrients or potentially harmful compounds.
  6. Context-dependent modulation of oxidative-stress and NRF2-linked cytoprotective pathways; this is secondary and varies substantially among individual foods.

Bioavailability / PK relevance: Conventional systemic pharmacokinetics are not applicable because fermented foods are complex dietary matrices rather than single molecular agents. Exposure is concentrated in the gastrointestinal tract and includes transient exposure to viable microbes, microbial components and locally generated metabolites. Some metabolites and transformed nutrients are systemically absorbed, but their concentrations vary with food composition, processing, host digestion and baseline microbiota. Pasteurization, cooking and prolonged storage can eliminate viable microorganisms while retaining some fermentation-derived metabolites.

In-vitro vs systemic exposure relevance: Direct cancer-cell experiments using concentrated fermented-food extracts, purified microbial metabolites or culture supernatants frequently use exposures that cannot be directly reproduced by ordinary dietary intake. Whole-food effects are primarily microbiome-mediated, luminal and host-metabolic rather than concentration-driven direct cytotoxicity. Results from one fermented product, microbial strain or extract should not be generalized to the entire category.

Clinical evidence status: Human dietary evidence is moderate for modulation of microbiome diversity, immune markers and selected cardiometabolic outcomes, but remains product-specific and heterogeneous. A controlled feeding trial reported increased microbiome diversity and reduced inflammatory markers during a high-fermented-food diet. Cancer-prevention evidence is predominantly observational and differs by food type, population and tumour site. Direct anticancer treatment evidence is preliminary, with pilot studies and isolated reports rather than definitive oncology RCTs. Fermented foods should therefore be classified as a supportive dietary exposure, not a demonstrated cancer treatment or substitute for standard therapy.


Examples: Cheese, Kefir, Fermented Dairy, Fermented Apple puree, Kombucha, Kochujang, Vinegar, Yogurt


Mechanistic Effects of Dietary Fermented Foods

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Gut microbiome composition and function ↓ tumour-supportive microbial signalling (context-dependent) ↑ microbial diversity and functional resilience G Microbiome modulation Effects depend on the food, viable microbial content, baseline diet and host microbiome. Food-associated organisms are often transient rather than permanently engrafting.
2 Intestinal epithelial barrier ↓ exposure to microbial inflammatory products (indirect) ↑ tight-junction integrity and mucosal defence (context-dependent) G Barrier support Organic acids, microbial components and altered resident microbiota may reduce permeability and endotoxin translocation. Evidence is stronger mechanistically than clinically.
3 Innate and adaptive immune regulation ↑ immune surveillance or antitumour responsiveness (model-dependent) ↓ excessive inflammatory activation and ↑ immune regulation G Immune-state modulation A controlled human dietary study found broad reductions in inflammatory proteins, but clinical oncology benefit has not been established.
4 NF-κB and inflammatory cytokine signalling ↓ pro-survival inflammatory signalling (indirect, model-dependent) ↓ IL-6, TNF-related and inflammatory signalling (context-dependent) G Reduced chronic inflammation The magnitude and direction vary among fermented dairy, soy, vegetable and beverage products.
5 Microbial metabolites and short-chain fatty-acid axis ↓ proliferation and ↑ differentiation or apoptosis in colorectal models (metabolite-dependent) ↑ colonocyte energy support and regulatory immune signalling G Metabolic and epigenetic modulation Fermented foods may supply metabolites directly or alter resident microbial metabolism. Butyrate-related effects are most relevant in the colon and should not be generalized systemically.
6 Food-derived bioactive transformation ↓ proliferation and survival pathways (high concentration only) ↑ nutrient accessibility and bioactive-metabolite exposure G Generation of bioactive compounds Fermentation can alter isoflavones, phenolics, peptides and vitamins. The resulting composition is highly product-specific.
7 Pathogen and pathobiont suppression ↓ microbe-associated tumour-promoting signals (indirect) ↓ pathogen colonization through organic acids, bacteriocins and competitive exclusion R/G Ecological competition Most evidence concerns gastrointestinal ecology and food preservation rather than direct tumour suppression.
8 Oxidative stress and NRF2 regulation ↑ or ↓ NRF2 and ROS responses (product-dependent) ↑ NRF2-linked cytoprotection and antioxidant capacity (context-dependent) R/G Secondary redox modulation Fermented-food extracts may increase tumour-cell ROS while protecting normal cells, but these findings generally involve concentrated experimental preparations.
9 Carcinogen and xenobiotic metabolism ↓ genotoxic exposure and DNA damage (indirect, model-dependent) ↑ detoxification or microbial sequestration of selected compounds G Modification of luminal carcinogen exposure Potential benefits are compound-specific. Some poorly controlled fermentations can instead generate undesirable metabolites or contamination.
10 Metabolic and glycemic regulation ↓ growth-supporting metabolic environment (indirect) ↓ fasting glucose, triglycerides or blood pressure in selected studies G Systemic metabolic support Observed effects are generally small and differ by product. They should not be presented as a uniform property of all fermented foods.
11 Clinical Translation Constraint ↔ unproven direct therapeutic effect ↔ variable benefit and tolerability G Heterogeneous exposure and limited oncology trials Major constraints include nonstandardized microbial composition, absent viable organisms in some products, variable doses, high sodium or sugar, biogenic amines, contamination risk and confounding by the overall dietary pattern.

P: 0–30 min    R: 30 min–3 hr    G: >3 hr
neuroP, neuroprotective: Click to Expand ⟱
Source:
Type:
Neuroprotective refers to the ability of a substance, intervention, or strategy to preserve the structure and function of nerve cells (neurons) against injury or degeneration.
-While cancer and neurodegenerative processes might seem distinct, there is significant overlap in terms of treatment-related neurotoxicity, shared molecular mechanisms, and the potential for therapies that provide neuroprotection during cancer treatment.
Scientific Papers found: Click to Expand⟱
6716- dietF,    Current Research in Fermented Foods: Bridging Tradition and Science
- Review, Nor, NA
*GutMicro↑, *Inflam↓, *BP↓, *LDL↓, *HDL↑, *CRP↓, *IL6↓, *TNF-α↓, *Obesity↓, *AntiDiabetic↑, *cardioP↑, *GutMicro↑, *neuroP↑, *cognitive↑,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Total Targets: 0

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

HDL↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

LDL↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

CRP↓, 1,   IL6↓, 1,   Inflam↓, 1,   TNF-α↓, 1,  

Clinical Biomarkers(tgid=22) ⓘ

BP↓, 1,   CRP↓, 1,   GutMicro↑, 2,   IL6↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiDiabetic↑, 1,   cardioP↑, 1,   cognitive↑, 1,   neuroP↑, 1,   Obesity↓, 1,  
Total Targets: 15

Scientific Paper Hit Count for: neuroP, neuroprotective
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:309  Target#:1105  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page